New pill targets tough cancers in early human trial

NCT ID NCT04905914

Completed Disease control Sponsor: Aprea Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to take pills by mouth and have a life expectancy of at least 3 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ATRN-119 (oral capsule)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific DNA repair mutations.
What could go wrong: This is an early-phase trial (Phase 1/2a) with only 132 participants, so it is too small to prove effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine

Philadelphia, Pennsylvania, 19104, United States
Mary Crowley Cancer Research

Dallas, Texas, 75230, United States
NEXT Oncology- San Antonio

San Antonio, Texas, 78229, United States
NEXT Oncology- Virginia

Fairfax, Virginia, 22031, United States
NEXT- Oncology Dallas

Irving, Texas, 75039, United States
University Hospitals, Cleveland Medical Center

Cleveland, Ohio, 44106, United States
Yale Cancer Center

New Haven, Connecticut, 06520-8028, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.